AMCP opposes government regulation of drug pricing because of the potential for unintended consequences and supports the elimination of barriers to competition to bring down the high cost of prescription drugs.
Legislative & Regulatory Positions
Stay up-to-date on recent legislative and regulatory developments and actions that AMCP has taken on behalf of members that impact managed care pharmacy professionals. AMCP's position statements are regularly reviewed and updated by the AMCP Board of Directors.
The Academy of Managed Care Pharmacy (AMCP) supports scientifically sound research that compares the effectiveness and value of prescription drugs, as well as research aimed at tailoring treatment options to individual patients’ needs.
AMCP supports the recognition of pharmacists as providers. When pharmacists are recognized as provider members of the health care team, patient outcomes improve, and patients report higher rates of satisfaction while overall health care costs are reduced. Recognized provider status would allow pharmacists to be reimbursed for providing health care services to patients. In a survey conducted in 2023 commissioned by Wolters Kluwer Health, 58% of Americans agreed that they are more likely to seek non-emergency medical care from a pharmacist.
AMCP supports increased access to Prescription Digital Therapeutics (PDTs). PDTs are software-based therapies that deliver clinical benefits to patients, either alone or in combination with other forms of treatment. These therapeutics require a prescription and are subject to oversight by the Food and Drug Administration (FDA). To be approved by the FDA, PDTs must demonstrate both safety and efficacy.
AMCP opposes legislative proposals that would allow the commercial importation of prescription drugs for sale in the United States
AMCP supports a wide range of measures that strike a balance between market-oriented principles and prudent regulations. Pharmacy benefit managers (PBMs) help facilitate patient access to medication at an affordable price.
AMCP opposes attempts to erode the Employee Retirement Income Security Act (ERISA) and Medicare Part D preemption. AMCP believes that the certainty that comes with a single uniform federal standard ensures that plans subject to these laws are better able to provide access to needed medications regardless of where the patient lives or works.
The rebate system is an important lever for ensuring the affordability of prescription medications and health care premiums for Americans. AMCP supports the use of a rebate system as one of many levers to help to control drug costs.
Use of appropriate medication regimens, regardless of cost, may help to improve patients’ conditions, improve quality of life, and lower other health care costs.
AMCP encourages the use of generic drugs as safe, cost- effective alternatives to the equivalent brand-name products
AMCP urges policymakers and stakeholders to reject the criminalization of medication dispensing in favor of rigorous scientific standards used to determine the safest and most effective care for patients.
AMCP supports efforts to reduce fraud, waste, and abuse in prescription drug benefit plans
